Acadia Pharmaceuticals Stock Alpha and Beta Analysis
| ACAD Stock | USD 26.71 0.01 0.04% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as ACADIA Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in ACADIA Pharmaceuticals over a specified time horizon. Remember, high ACADIA Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to ACADIA Pharmaceuticals' market risk premium analysis include:
Beta 1.54 | Alpha 0.28 | Risk 2.26 | Sharpe Ratio 0.16 | Expected Return 0.35 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out ACADIA Pharmaceuticals Backtesting, ACADIA Pharmaceuticals Valuation, ACADIA Pharmaceuticals Correlation, ACADIA Pharmaceuticals Hype Analysis, ACADIA Pharmaceuticals Volatility, ACADIA Pharmaceuticals History and analyze ACADIA Pharmaceuticals Performance. ACADIA Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. ACADIA Pharmaceuticals market risk premium is the additional return an investor will receive from holding ACADIA Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ACADIA Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate ACADIA Pharmaceuticals' performance over market.| α | 0.28 | β | 1.54 |
ACADIA Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of ACADIA Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how ACADIA Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.ACADIA Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how ACADIA Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading ACADIA Pharmaceuticals shares will generate the highest return on investment. By understating and applying ACADIA Pharmaceuticals stock market price indicators, traders can identify ACADIA Pharmaceuticals position entry and exit signals to maximize returns.
ACADIA Pharmaceuticals Return and Market Media
The median price of ACADIA Pharmaceuticals for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 23.1 with a coefficient of variation of 10.34. The daily time series for the period is distributed with a sample standard deviation of 2.45, arithmetic mean of 23.73, and mean deviation of 2.13. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | ACADIA Pharmaceuticals Inc. stock trend outlook and recovery path - Day Trade Reliable Breakout Stock Forecasts - newser.com | 10/20/2025 |
2 | Is ACADIA Pharmaceuticals Inc. stock trading near support levels - Weekly Trade Summary Low Risk Growth Stock Ideas - newser.com | 11/03/2025 |
3 | Disposition of 30000 shares by Daly James M of ACADIA Pharmaceuticals at 22.3661 subject to Rule 16b-3 | 11/10/2025 |
4 | Los Angeles Capital Management LLC Lowers Stock Position in ACADIA Pharmaceuticals Inc. ACAD | 11/13/2025 |
5 | Disposition of 4084 shares by James Kihara of ACADIA Pharmaceuticals at 23.6909 subject to Rule 16b-3 | 11/18/2025 |
6 | Heres Why Acadia Pharmaceuticals is a Strong Momentum Stock | 11/28/2025 |
7 | Acadia Stock Up 59 percent in a Year Is a 51 Million New Stake a Bet on a Bigger Rebound - The Motley Fool | 12/03/2025 |
8 | Acadia Pharmaceuticals Reassessing Valuation After Strong Q3 Earnings Beat and Higher Analyst Price Targets | 12/05/2025 |
9 | ACADIA Pharmaceuticals Inc. ACAD Stock Holdings Boosted by Walleye Capital LLC | 12/09/2025 |
10 | Acadia Pharmaceuticals Announces FDA Approval of DAYBUE STIX for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome | 12/12/2025 |
11 | Research Analysts Offer Predictions for ACAD FY2028 Earnings | 12/18/2025 |
12 | Movement Within Algorithmic Entry Frameworks - Stock Traders Daily | 12/29/2025 |
About ACADIA Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including ACADIA or other stocks. Alpha measures the amount that position in ACADIA Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 0.8 | 2.61 | 5.05 | 4.8 | Days Of Inventory On Hand | 238.26 | 285.89 | 97.89 | 93.0 |
ACADIA Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of ACADIA Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACADIA Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of ACADIA Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of ACADIA Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ACADIA Pharmaceuticals' management manipulating its earnings.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with ACADIA Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out ACADIA Pharmaceuticals Backtesting, ACADIA Pharmaceuticals Valuation, ACADIA Pharmaceuticals Correlation, ACADIA Pharmaceuticals Hype Analysis, ACADIA Pharmaceuticals Volatility, ACADIA Pharmaceuticals History and analyze ACADIA Pharmaceuticals Performance. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
ACADIA Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.